Latest Breaking News On - Jason rando - Page 3 : comparemela.com
Published: Jan 26, 2021
DELRAY BEACH, Fla., Jan. 26, 2021 (GLOBE NEWSWIRE) AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today announced the activation of two additional clinical trial sites in Poland for the extension arm of the Phase 2b OPTION 2 study investigating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).
Additional sites were added in Europe to minimize any potential patient enrollment delays during the ongoing COVID-19 pandemic. The two sites in Poland, as well as the active clinical trial sites in the U.S., are actively enrolling patients, and the Company anticipates reporting topline data during the first quarter 2021.
New-yorkUnited-statesFloridaBostonMassachusettsCaliforniaPolandDelray-beachJason-randoHans-vitzthumJames-sapirsteinLifesci-advisors